Article
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
The oncologist - 1 Apr 2014
Hanaizi Zahra, Unkrig Christoph, Enzmann Harald, Camarero Jorge, Sancho-Lopez Arantxa, Salmonson Tomas, Gisselbrecht Christian, Laane Edward, Pignatti Francesco
Abstract excerpt
On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (Bosulif) for the treatment of adult patients with chronic-phase, accelerated-phase, and blast-phase Philadelphia chromosome positive (Ph⁺) chronic myelogenous leukemia (CML) prev...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.